Blockage of interleukin-1β with canakinumab in patients with Covid-19

  1. Landi, Lorenza
  2. Ravaglia, Claudia
  3. Russo, Emanuele
  4. Cataleta, Pierluigi
  5. Fusari, Maurizio
  6. Boschi, Andrea
  7. Giannarelli, Diana
  8. Facondini, Francesca
  9. Valentini, Ilaria
  10. Panzini, Ilaria
  11. Lazzari-Agli, Luigi
  12. Bassi, Paolo
  13. Marchionni, Elisa
  14. Romagnoli, Rossella
  15. De Giovanni, Raffaella
  16. Assirelli, Marina
  17. Baldazzi, Federica
  18. Pieraccini, Fabio
  19. Rametta, Giovanna
  20. Rossi, Lucia
  21. Santini, Luca
  22. Valenti, Ivana
  23. Cappuzzo, Federico

Download
s41598-020-78492-y.pdf 1019,18KB
WeightNameValue
1000 Titel
  • Blockage of interleukin-1β with canakinumab in patients with Covid-19
1000 Autor/in
  1. Landi, Lorenza |
  2. Ravaglia, Claudia |
  3. Russo, Emanuele |
  4. Cataleta, Pierluigi |
  5. Fusari, Maurizio |
  6. Boschi, Andrea |
  7. Giannarelli, Diana |
  8. Facondini, Francesca |
  9. Valentini, Ilaria |
  10. Panzini, Ilaria |
  11. Lazzari-Agli, Luigi |
  12. Bassi, Paolo |
  13. Marchionni, Elisa |
  14. Romagnoli, Rossella |
  15. De Giovanni, Raffaella |
  16. Assirelli, Marina |
  17. Baldazzi, Federica |
  18. Pieraccini, Fabio |
  19. Rametta, Giovanna |
  20. Rossi, Lucia |
  21. Santini, Luca |
  22. Valenti, Ivana |
  23. Cappuzzo, Federico |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-12-11
1000 Erschienen in
1000 Quellenangabe
  • 10:21775
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1038/s41598-020-78492-y |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733468/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • There is the urgent need to study the effects of immunomodulating agents as therapy for Covid-19. An observational, cohort, prospective study with 30 days of observation was carried out to assess clinical outcomes in 88 patients hospitalized for Covid-19 pneumonia and treated with canakinumab (300 mg sc). Median time from diagnosis of Covid-19 by viral swab to administration of canakinumab was 7.5 days (range 0–30, IQR 4–11). Median PaO2/FiO2 increased from 160 (range 53–409, IQR 122–210) at baseline to 237 (range 72–533, IQR 158–331) at day 7 after treatment with canakinumab (p < 0.0001). Improvement of oxygen support category was observed in 61.4% of cases. Median duration of hospitalization following administration of canakinumab was 6 days (range 0–30, IQR 4–11). At 7 days, 58% of patients had been discharged and 12 (13.6%) had died. Significant differences between baseline and 7 days were observed for absolute lymphocyte counts (mean 0.60 vs 1.11 × 109/L, respectively, p < 0.0001) and C-reactive protein (mean 31.5 vs 5.8 mg/L, respectively, p < 0.0001).Overall survival at 1 month was 79.5% (95% CI 68.7–90.3). Oxygen-support requirements improved and overall mortality was 13.6%. Confirmation of the efficacy of canakinumab for Covid-19 warrants further study in randomized controlled trials.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal Diseases
lokal Medical research
lokal Health care
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/TGFuZGksIExvcmVuemE=|https://frl.publisso.de/adhoc/uri/UmF2YWdsaWEsIENsYXVkaWE=|https://frl.publisso.de/adhoc/uri/UnVzc28sIEVtYW51ZWxl|https://frl.publisso.de/adhoc/uri/Q2F0YWxldGEsIFBpZXJsdWlnaQ==|https://frl.publisso.de/adhoc/uri/RnVzYXJpLCBNYXVyaXppbw==|https://frl.publisso.de/adhoc/uri/Qm9zY2hpLCBBbmRyZWE=|https://frl.publisso.de/adhoc/uri/R2lhbm5hcmVsbGksIERpYW5h|https://frl.publisso.de/adhoc/uri/RmFjb25kaW5pLCBGcmFuY2VzY2E=|https://frl.publisso.de/adhoc/uri/VmFsZW50aW5pLCBJbGFyaWE=|https://frl.publisso.de/adhoc/uri/UGFuemluaSwgSWxhcmlh|https://frl.publisso.de/adhoc/uri/TGF6emFyaS1BZ2xpLCBMdWlnaQ==|https://frl.publisso.de/adhoc/uri/QmFzc2ksIFBhb2xv|https://frl.publisso.de/adhoc/uri/TWFyY2hpb25uaSwgRWxpc2E=|https://frl.publisso.de/adhoc/uri/Um9tYWdub2xpLCBSb3NzZWxsYQ==|https://frl.publisso.de/adhoc/uri/RGUgR2lvdmFubmksIFJhZmZhZWxsYQ==|https://frl.publisso.de/adhoc/uri/QXNzaXJlbGxpLCBNYXJpbmE=|https://frl.publisso.de/adhoc/uri/QmFsZGF6emksIEZlZGVyaWNh|https://frl.publisso.de/adhoc/uri/UGllcmFjY2luaSwgRmFiaW8=|https://frl.publisso.de/adhoc/uri/IFJhbWV0dGEsIEdpb3Zhbm5h|https://frl.publisso.de/adhoc/uri/Um9zc2ksIEx1Y2lh|https://frl.publisso.de/adhoc/uri/U2FudGluaSwgTHVjYQ==|https://frl.publisso.de/adhoc/uri/VmFsZW50aSwgSXZhbmE=|https://frl.publisso.de/adhoc/uri/Q2FwcHV6em8sIEZlZGVyaWNv
1000 Label
1000 Förderer
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
  1. Blockage of interleukin-1β with canakinumab in patients with Covid-19
    Blockage of interleukin-1β with canakinumab in patients with Covid-19
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer http://www.w3.org/1999/02/22-rdf-syntax-ns#nil |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6425914.rdf
1000 Erstellt am 2021-03-03T10:06:54.044+0100
1000 Erstellt von 5
1000 beschreibt frl:6425914
1000 Bearbeitet von 25
1000 Zuletzt bearbeitet 2021-03-11T07:47:36.657+0100
1000 Objekt bearb. Thu Mar 11 07:47:20 CET 2021
1000 Vgl. frl:6425914
1000 Oai Id
  1. oai:frl.publisso.de:frl:6425914 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source